Evidence map›Paper›PMID 36071499›Full record

ArticleOrphanet journal of rare diseases2022

Fibrodysplasia ossificans progressiva in Brazil: challenges and strategies to create assistance and educational networks.

Alessandro Rozim Zorzi, Patricia R Delai, Henrique L C Rosa, Wander E Brito, Victor A M Montalli, Juliana C Napimoga, Marcelo H Napimoga, Francisco H Nociti

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Orphanet journal of rare diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alessandro Rozim ZorziCenter of Rare Diseases at Faculdade São Leopoldo Mandic (DoRa), R José Rocha Junqueira, 13, Campinas, SP, 13045-755, Brazil. alessandro.zorzi@slmandic.edu.br.ORCID 0000-0003-0026-2724
Patricia R DelaiCenter of Rare Diseases at Faculdade São Leopoldo Mandic (DoRa), R José Rocha Junqueira, 13, Campinas, SP, 13045-755, Brazil.
Henrique L C RosaFaculdade São Leopoldo Mandic Medical School, Undergraduate Medical Program, Campinas, SP, Brazil.
Wander E BritoCenter of Rare Diseases at Faculdade São Leopoldo Mandic (DoRa), R José Rocha Junqueira, 13, Campinas, SP, 13045-755, Brazil.
Victor A M MontalliCenter of Rare Diseases at Faculdade São Leopoldo Mandic (DoRa), R José Rocha Junqueira, 13, Campinas, SP, 13045-755, Brazil.
Juliana C NapimogaCenter of Rare Diseases at Faculdade São Leopoldo Mandic (DoRa), R José Rocha Junqueira, 13, Campinas, SP, 13045-755, Brazil.
Marcelo H NapimogaCenter of Rare Diseases at Faculdade São Leopoldo Mandic (DoRa), R José Rocha Junqueira, 13, Campinas, SP, 13045-755, Brazil.
Francisco H NocitiCenter of Rare Diseases at Faculdade São Leopoldo Mandic (DoRa), R José Rocha Junqueira, 13, Campinas, SP, 13045-755, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibrodysplasia ossificans progressiva (FOP) is an ultrarare condition and one of the most impactful disorders associated with progressive heterotopic ossification events. It is estimated that there are 120-150 patients in Brazil; however, currently, fewer than 100 patients have been identified, and the role of a FOP advocacy group (FOP Brazil) has been instrumental for the identification and follow-up of these individuals and families. The aim of this article is to summarize the current status of FOP in Brazil and describe strategies proposed to approach this challenge in a continental size country.

Indexed as

Myositis OssificansOssification, HeterotopicBrazilHumansFibrodysplasia ossificans progressivaGenetic diseasesHeterotopic ossificationRare diseases

Identifiers

PMID36071499
PMCPMC9450346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.